or Try an Advanced Search...

    Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.

    Grade Last Price % Change Price Change
    C 21.12 -0.17% -0.04
    CPRX closed down 1.12 percent on Wednesday, November 20, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Flat Down
    Historical CPRX trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish -0.17%
    NR7 Range Contraction -0.17%
    NR7-2 Range Contraction -0.17%
    Oversold Stochastic Weakness -0.17%
    Crossed Above 50 DMA Bullish -1.29%
    NR7 Range Contraction -1.29%
    NR7-2 Range Contraction -1.29%
    Oversold Stochastic Weakness -1.29%
    50 DMA Resistance Bearish 1.42%
    NR7 Range Contraction 1.42%
    Older End-of-Day Signals for CPRX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 20 hours ago
    50 DMA Support about 24 hours ago
    Down 1% about 24 hours ago
    Up 1% about 24 hours ago
    Rose Above Previous Day's High 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CPRX Chart by TradingView
    Basic chart:

    Profile

    Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Health Sciences Medication Virotherapy Disorders Epilepsy Prescription Drugs Pharmaceutical Sciences Myasthenia Stage Specialty Pharmaceutical Pharmaceutical Partners Treatment Of Epilepsy Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome Urological Diseases

    Is CPRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
    Nov 13 Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
    Nov 13 Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point
    Nov 11 Vericel Stock Sees RS Rating Shoot Higher
    Nov 10 Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
    Nov 8 With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
    Nov 7 Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript
    Nov 7 Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?
    Nov 6 Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say
    Nov 6 Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
    See more CPRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 24.27
    52 Week Low 13.0
    Average Volume 995,277
    200-Day Moving Average 17.53
    50-Day Moving Average 21.09
    20-Day Moving Average 22.01
    10-Day Moving Average 22.21
    Average True Range 0.77
    RSI (14) 45.65
    ADX 26.13
    +DI 21.78
    -DI 25.56
    Chandelier Exit (Long, 3 ATRs) 21.97
    Chandelier Exit (Short, 3 ATRs) 22.74
    Upper Bollinger Bands 23.76
    Lower Bollinger Band 20.27
    Percent B (%b) 0.25
    BandWidth 15.83
    MACD Line 0.11
    MACD Signal Line 0.37
    MACD Histogram -0.2578
    Fundamentals Value
    Market Cap 2.52 Billion
    Num Shares 119 Million
    EPS 0.55
    Price-to-Earnings (P/E) Ratio 38.45
    Price-to-Sales 4.66
    Price-to-Book 4.66
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.02
    Resistance 3 (R3) 22.08 21.86 21.88
    Resistance 2 (R2) 21.86 21.64 21.83 21.83
    Resistance 1 (R1) 21.50 21.50 21.39 21.44 21.78
    Pivot Point 21.28 21.28 21.22 21.25 21.28
    Support 1 (S1) 20.92 21.06 20.81 20.86 20.52
    Support 2 (S2) 20.70 20.92 20.67 20.47
    Support 3 (S3) 20.34 20.70 20.43
    Support 4 (S4) 20.28